BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amarantus MA Gains Media Attention with Parkinson's Drug Candidate


8/17/2011 1:41:17 PM

August 17, 2011 -- Amarantus BioSciences Inc. (OTCBB: AMBS), a biotechnology company focused on a therapeutic protein that addresses apoptosis, similar to companies like InVivo Therapeutics Corp (OTCBB: NVIV) and Roche Holdings Ltd. (Pink Sheets: RHHBY), is gaining strong media attention with its Parkinson’s Disease drug candidate that is currently in clinical trials.

Amarantus BioSciences Inc. (OTCBB: AMBS) is a biotechnology company focused on developing a therapeutic protein that addresses apoptosis – or cell death. By utilizing MANF, a highly-potent neurotrophic factor, the company hopes to treat a number of apoptosis-related diseases and conditions, including Parkinson’s Disease and Ischemic Heart Disease.

Neurotrophic factors are proteins that promote the survival, growth and function of neurons in the brain. Since Parkinson’s Disease is characterized by the death of dopamine neurons, these proteins are of great interest to researchers in the space. Preventing the death of these cells could reduce the motor and other adverse symptoms associated with the disease.

To learn more about MANF and its impact on Parkinson’s Disease, see the company’s website: http://www.amarantus.com/therapeutic-development/parkinsons-disease.html

Amarantus Partners to Combat Parkinson’s Disease

In April of 2010, Amarantus BioSciences received a research grant from the Michael J. Fox Foundation to finance a study of the efficacy of MANF for the treatment of Parkinson’s Disease. These early-stage preclinical results suggested that MANF could be as effective or more effective than GDNF, another neurotrophic factor that has already undergone more rigorous testing.

Currently, the only therapies approved to treat Parkinson’s Disease only treat the symptoms and not the underlying causes. As a result, there is an urgent medical need for curative treatments that fill the fundamental gap in treatment by arresting disease progression. While MANF is still in clinical trials, early results suggest that it may safely and efficaciously promote dopamine producing neuron development.

Recently, the Michael J. Fox Foundation also published a prospectus on the topic:

http://biotechstocktrader.com/amarantus-biosciences-ambs-interviewed-by-michael-j-fox-foundation-270/

Early-Stage Investors Could Benefit from Catalysts

Early-stage biotechnology investors may want to take a closer look at Amarantus BioSciences Inc. (OTCBB: AMBS). With a market capitalization of just $25 million, the market has yet to price in any successful developments for its treatments for not only Parkinson’s Disease, but also a range of other conditions including diabetes and Ischemic Heart Disease.

Meanwhile, the biotechnology company also has significant long-term potential in the form of its PhenoGuard Cell Line Library. As a pioneer in the development of immortalized mammalian cells that retain the phenotype of their parent cell, the company’s 80 cell lines could target a wide array of disease and conditions in a way never before possible.

For more information about Amarantus BioSciences, please visit their website:

http://www.amarantus.com/

Or, view their latest 10-K filing at SECFilings.com:

http://secfilings.com/SearchResults.aspx?ticker=&name=amarantus



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES